Overview

A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions

Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This research study is studying a drug as a possible treatment for ALK-positive or ROS1-positive non-small cell lung cancer (NSCLC). The following drug will be involved in this study : - Lorlatinib
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital